BGM Group Ltd.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a BGM research report →
Price Chart
About the company
Operating from Chengdu, People's Republic of China, BGM Group Ltd. engages in the manufacturing and supply of active pharmaceutical ingredients (APIs), traditional Chinese medicine (TCM) derivatives, and various other related products across China. The company's pharmaceutical portfolio includes an array of licorice-based items: Gan Di Xin, an oral medication for cough and expectorant relief; Qilian Shan Licorice Extract, serving as a raw material for pharmaceutical firms to produce conventional licorice tablets; and Qilian Shan licorice liquid extract, a key ingredient utilized by medical preparers for crafting compound licorice oral solutions.
- CEO
- Chen Xin
- IPO
- 2021
- Employees
- 298
- HQ
- Chengdu, SIC, CN
Get TickerSpark's AI analysis on BGM
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $100.22M
- P/E
- -1.61
- PEG
- 0.00
- P/S
- 2.64
- P/B
- 0.09
- EV/EBITDA
- -8.30
- Div Yield
- 0.00%
- Gross Margin
- 12.79%
- Op Margin
- -33.18%
- Net Margin
- -52.59%
- ROE
- -6.96%
- ROIC
- -3.19%
Latest fiscal year · YoY change
- Revenue
- $37.92M+51.1%
- Gross Profit
- $4.85M+17.8%
- Op Income
- $-12,581,664
- Net Income
- $-19,941,242-1282.1%
- EPS
- $-0.18+10.0%
- OCF Growth
- -535.9%
- FCF Growth
- -31.0%
- 52W High
- $11.80
- 52W Low
- $0.25
- 50D MA
- $0.32
- 200D MA
- $2.23
- Beta
- 1.81
- RSI (14)
- 40
- Avg Volume
- 418.42K
No earnings-call transcripts are available for BGM yet.
- Free Float
- 22.9%
- Shares Outstanding
- 380.62M
- Float Shares
- 87.10M
of shares held by institutions
8 13F filers
Held by 1 ETFs
Biggest fund positions in BGM by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Mar 31, 26 | ren yuehua | other | 0 |
| Mar 31, 26 | ZHAI Yaxuan | other | 0 |
| Mar 31, 26 | XU WAIHUA | other | 0 |
| Apr 28, 26 | Lou Zefei | other | 0 |
| Apr 13, 26 | ZHANG LIN (Henry) | other | 0 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our BGM coverage
Recent articles, reports, and earnings notes.
No research on BGM yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate BGM report →BGM Group Ltd. (NASDAQ:BGM) Short Interest Down 13.0% in February
defenseworld.net · Mar 18
BGM Group Ltd. Receives NASDAQ Notice Related to Late Filing of Form 20-F
globenewswire.com · Feb 26
BGM Group (NASDAQ:BGM) Stock Price Down 1% – Should You Sell?
defenseworld.net · Feb 21
BGM Group (NASDAQ:BGM) vs. Rhythm Pharmaceuticals (NASDAQ:RYTM) Financial Contrast
defenseworld.net · Feb 10
BGM Group: I Think I Found An Undervalued Stock
seekingalpha.com · Sep 24
BGM To Report First Half 2025 Unaudited Financial Results on July 24, 2025
prnewswire.com · Jul 23
What Is Behind BGM Stock's 90%+ Surge This Year
benzinga.com · Jun 11
From Virtual Agents to Embodied and Industry-Specific AI: BGM Acquires Xingdao Intelligent and YD Network, Advancing AI on Two Fronts
prnewswire.com · May 28
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.